Adoptive cell transfer

AVM Biotechnology Selected by the National Cancer Institute to Present at Bio Investor Forum 2023

Retrieved on: 
Monday, September 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NIDDK, Pancreatic cancer, Human, Drug development, NOD, Bio, SBIR, Bone marrow, NHL, National Institutes of Health, Clinical trial, Cancer, Multimedia, Research, Natural killer T cell, National Cancer Institute, Type 1, AVM, Patient, Adoptive cell transfer, Animal, Growth, FDA, NCI, Service, Safety, Pharmaceutical industry, Vaccine, TCR

With a solid pipeline behind AVM0703, AVM Biotechnology is well positioned for significant growth in 2023-2024.

Key Points: 
  • With a solid pipeline behind AVM0703, AVM Biotechnology is well positioned for significant growth in 2023-2024.
  • (Graphic: Business Wire)
    In June 2023, AVM Biotechnology was selected as a 2023-2024 National Cancer Institute (NCI) Showcase Company for their Small Business Innovation Research (SBIR) Investor Initiatives.
  • AVM Biotechnology has previously been awarded five (5) highly competitive National Institute of Health SBIR grants; three (3) of these from the National Cancer Institute.
  • AVM Biotechnology is a clinical stage company headquartered in Seattle, WA developing immunomodulatory therapies for hematological cancer, infectious and autoimmune diseases.

AVM Biotechnology Announces that the National Cancer Institute has selected AVM Biotechnology as a Showcase Company for their 2023-2024 Small Business Innovation Research (SBIR) Investor Initiatives

Retrieved on: 
Wednesday, August 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NIDDK, Human, Drug development, NOD, OrbiMed, CSO, SBIR, Clinical trial, Bone marrow, NHL, National Institutes of Health, Cancer, Multimedia, Research, National Cancer Institute, CAR, Type 1, Animal, AVM, Patient, Adoptive cell transfer, AbbVie, Johnson & Johnson, American Cancer Society, Leukemia, FDA, NCI, Safety, Disease, Pharmaceutical industry, TCR

AVM Biotechnology has been selected as a 2023-2024 National Cancer Institute (NCI) showcase company for the SBIR Investor Initiatives.

Key Points: 
  • AVM Biotechnology has been selected as a 2023-2024 National Cancer Institute (NCI) showcase company for the SBIR Investor Initiatives.
  • AVM Biotechnology has previously been awarded five (5) highly competitive National Institute of Health SBIR grants; three (3) of these from the NCI.
  • Dr. Deisher and the entire team at AVM Biotechnology are committed to bringing drugs to cancer patients that fight the cancer, not the patient.
  • (Photo: Business Wire)
    “We are excited to have been selected, after competitive review, to be a 2023-2024 showcase company for the NCI’s SBIR Investor Initiative.

AVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients have been Treated with Immunomodulatory AVM0703 through Expanded Access/Compassionate Use Programs

Retrieved on: 
Tuesday, August 1, 2023
Oncology, Health, Consumer, Seniors, Clinical Trials, Pharmaceutical, Biotechnology, NIDDK, Marketing, Pain, Medsafe, Adoptive cell transfer, Patient, Carcinoma, Leukemia, Prostate cancer, Disease, Human, EAP, DLBCL, SBIR, Expanded access, Physician, Bone marrow, Research, Lung cancer, Glioblastoma, CUP, Cancer, Type 1, FDA, NCI, Safety, NOD, Desmoplastic small-round-cell tumor, Multimedia, Medicine, CAR, National Cancer Institute, Animal, B-ALL, Otorhinolaryngology, Drug development, Clinical trial, NHL, National Institutes of Health, Medication, CNS, Sale, AVM, American Cancer Society, Nursing, Vaccine, Pharmaceutical industry, Medical device, TCR

Requests for additional information about immunomodulatory AVM0703 and its relatively broad activity against solid tumors and blood cancers can be made by contacting [email protected] .

Key Points: 
  • Requests for additional information about immunomodulatory AVM0703 and its relatively broad activity against solid tumors and blood cancers can be made by contacting [email protected] .
  • “AVM Biotechnology is committed to providing AVM0703 to patients who cannot participate in our enrolling clinical trial.
  • Our team at AVM Biotechnology is dedicated to providing hope to patients and their loved ones.” Theresa Deisher, AVM Biotechnology , Founder and CEO.
  • AVM Biotechnology is a clinical stage company headquartered in Seattle, WA developing immunomodulatory therapies for hematological cancer, infectious and autoimmune diseases.

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

Retrieved on: 
Monday, October 10, 2022
808, U.S. Securities and Exchange Commission, Securities Act of 1933, Telephone, Sale, SEC, SVB, Investment, LLC, NASDAQ, Jefferies Group, Patient, Madison Avenue, Attention, LP, Cancer, State Street, Adoptive cell transfer, Prospectus, Jefferies, Forward-looking statement, Terminology, Wellington Management Company, Security (finance)

The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $110 million.

Key Points: 
  • The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $110 million.
  • The offering is expected to close on October 12, 2022, subject to customary closing conditions.
  • Jefferies and SVB Securities are acting as joint book-running managers for the offering.
  • For example, statements concerning the closing of the public offering and gross proceeds therefrom are forward-looking statements.

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

Retrieved on: 
Monday, October 10, 2022
TCR, LinkedIn, DL, Engineering, CRS, SEC, Webcast, Head, Investor, Neoplasm, DLT, RECIST, Patient, Cytokine release syndrome, Twitter, SD, Evelyn, Cancer Prevention and Research Institute of Texas, Cancer, Research institute, CT, Trial of the century, Ovarian cancer, MD, PRAME, Â, Adoptive cell transfer, ORR, Nature, CEST, Safety, EDT, Cancer prevention, Melanoma, Clinical trial, Forward-looking statement, Corr, Terminology, Uveal melanoma, Half-life, University of Texas Health Science Center at Houston, Medical imaging, Pharmaceutical industry, Vaccine

In addition to this first data from IMA203 monotherapy today, we are awaiting data from two additional dose expansion cohorts: IMA203 together with an immune checkpoint inhibitor and our 2nd generation product candidate IMA203CD8.

Key Points: 
  • In addition to this first data from IMA203 monotherapy today, we are awaiting data from two additional dose expansion cohorts: IMA203 together with an immune checkpoint inhibitor and our 2nd generation product candidate IMA203CD8.
  • Safety data for IMA203 monotherapy across Phase 1a and Phase 1b: Treatment with IMA203 continues to show manageable tolerability profile.
  • Phase 1b Cohort A - Clinical activity: IMA203 monotherapy demonstrates high confirmed objective response rate of 80% with early signs of prolonged durability.
  • Immatics will host a conference call today, October 10, 2022, at 8:30 am EDT / 2:30pm CEST to discuss these clinical data.

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
Saturday, September 10, 2022
Pharmacokinetics, Terminology, NASDAQ, Toxic shock syndrome toxin, Population, Mouse, PRAME, Half-life, Clinical trial, Oncology, Toxicity, Trial of the century, Congress, Cancer, Cytokine release syndrome, SEC, HLA, European Society of Gene and Cell Therapy, Nature, LinkedIn, European Society for Medical Oncology, ESMO, Safety, TCR, Adoptive cell transfer, Forward-looking statement, Patient, Neoplasm, Twitter, Fine chemical, Pharmaceutical industry, Vaccine, Instagram

Immatics TCER molecules are "off-the-shelf"TCR Bispecifics engineered with two binding regions: a TCR domain and a T cell recruiter domain.

Key Points: 
  • Immatics TCER molecules are "off-the-shelf"TCR Bispecifics engineered with two binding regions: a TCR domain and a T cell recruiter domain.
  • The promising preclinical results for our next-generation, half-life extended TCER IMA402 reflect the potential of our TCR Bispecific approach for patients with solid tumors, commented Carsten Reinhardt, M.D., Ph.D., Chief Development Officer at Immatics.
  • We look forward to initiating the IMA402 Phase 1/2 clinical trial in 2023 as part of our strategy to tackle PRAME with two distinct therapeutic modalities.
  • HLA-A*02:01-positive patients with different solid tumors expressing PRAME will initially receive weekly infusions of IMA402.

Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Thursday, September 8, 2022
ACT, Adoptive cell transfer, Security (finance), NYSE, BMT, ARC, Toxic epidermal necrolysis, Radiation, SEC, Patent, U.S. Securities and Exchange Commission, Antibody, Conference, Company, FDA, ARCS, AWE, Form 10-Q, Relapse, Lotte New York Palace Hotel, CD19, Annual report, Patient, Pharmaceutical industry, Actinium

NEW YORK, Sept. 8, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will be participating in theH.C.Wainwright 24th Annual Global Investment Conference, being held September 12-14, 2022.

Key Points: 
  • NEW YORK, Sept. 8, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will be participating in theH.C.Wainwright 24th Annual Global Investment Conference, being held September 12-14, 2022.
  • The conference will be hybrid and occur virtually and in person at the Lotte New York Palace Hotel in New York City.
  • Please contact your representative at H.C. Wainwright to schedule a one-on-one meeting with the Actinium management team.
  • For information about the H.C. Wainwright Global Investment Conference, please refer to the event's website .

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

Retrieved on: 
Tuesday, August 23, 2022
Literature, Neoplasm, Patient, Adoptive cell transfer, Cancer, PRAME, Synovial sarcoma, NASDAQ, Engineering, Evelyn, Nature, CD8, Head, Interim, Nivolumab, Body surface area, LinkedIn, Forward-looking statement, SEC, Cell, Uveal melanoma, CD4, University of Texas Health Science Center at Houston, Population, Twitter, CD19, Terminology, Clinical trial, Melanoma, Trial of the century, TCR, SITC, Vaccine, Medical imaging, Pharmaceutical industry, Instagram

The 2nd generation TCR-T IMA203CD8 aims to further enhance depth and durability of anti-tumor responses and clinical outcomes of TCR-T targeting PRAME in patients with solid cancers.

Key Points: 
  • The 2nd generation TCR-T IMA203CD8 aims to further enhance depth and durability of anti-tumor responses and clinical outcomes of TCR-T targeting PRAME in patients with solid cancers.
  • PRAME is highly prevalent across several indications thereby supporting the programs potential to reach a broad patient population.
  • Todays milestone brings us closer to our goal of achieving long-lasting responses for a broad range of cancer patients having solid tumors that express PRAME.
  • The 2nd generation TCR-T IMA203CD8 is part of Immatics strategy to realize the full clinical potential of IMA203 TCR-T targeting PRAME.

Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer

Retrieved on: 
Wednesday, August 3, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pediatrics, Lymphatic system, TCR, HCC, Liver cancer, GPC3, Patient, Jiaotong University, Multimedia, Food, First Affiliated Hospital of Zhengzhou University, List of life sciences, Organic acid, Protein, Hepatocellular carcinoma, Safety, AFP, Cancer, Antigen, First Affiliated Hospital of Xinjiang Medical University, Adoptive cell transfer, Antibody, The First Affiliated Hospital of Wenzhou Medical University, HLA, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, MHC, Serum, Notre Dame, University, Immunotherapy, Vaccine, San Francisco Bay Area

Alpha-fetoprotein (AFP) is an intracellular antigen found in hepatocellular carcinoma (HCC), the predominant type of liver cancer.

Key Points: 
  • Alpha-fetoprotein (AFP) is an intracellular antigen found in hepatocellular carcinoma (HCC), the predominant type of liver cancer.
  • In a previous study, Eureka reported that an engineered TCRm targeting alpha-fetoprotein (AFP)-MHC complex can effectively redirect CAR-T cells against liver cancer cells.
  • In this study, the crystal structure showed the AFP-MHC targeting TCRm antibody binding directly over the center of the HLA protein.
  • A third trial ( ARYA-3 ) targets the GPC3 protein, also found on liver cancer cells, with ARTEMIS T cells (ECT204).

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

Retrieved on: 
Tuesday, June 7, 2022
Intellectual property, Gene editing, Neoplasm, Patent, LinkedIn, Annual report, Forward-looking statement, Partnership, Security (finance), CRISPR, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Nasdaq, GLOBE, Patient, Technology, Harvard University, EDIT, SEC, Twitter, Clinical trial, Adoptive cell transfer, Cancer, Terminology, Pharmaceutical industry, Vaccine, Medical imaging, Editas Medicine, Instagram

As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicines CRISPR technology and intellectual property.

Key Points: 
  • As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicines CRISPR technology and intellectual property.
  • Editas Medicine is the exclusive licensee of Harvard and Broad Institutes Cas9 patent estates and Broad Institutes Cas12a patent estate for human medicines.
  • We believe that our gene editing technology can modulate and enhance the potential of cell therapies to deliver transformative medicines for the treatment of cancer.
  • Except as required by law, Editas Medicine explicitly disclaims any obligation to update any forward-looking statements.